Physician profile
Roshnara Singh
NPI 1881673838
$2,220.28
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $572 · 2020: $312 · 2021: $594 · 2022: $380 · 2023: $313 · 2024: $49.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $262 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $262.40 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $372.31 | 2019-2023 | Lo Loestrin Fe |
| Applied Medical Resources Corporation | $279.83 | 2021 | |
| Astellas Pharma US INC | $174.72 | 2020-2023 | Myrbetriq, Veozah |
| Amag Pharmaceuticals, INC. | $169.33 | 2019 | |
| Pfizer INC. | $140.19 | 2019-2024 | |
| Daiichi Sankyo INC. | $139.96 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $120.66 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $89.33 | 2019-2020 | |
| Therapeuticsmd, INC. | $84.71 | 2019-2022 | |
| Avion Pharmaceuticals | $72.54 | 2019-2020 | |
| Hologic Sales and Service, LLC | $69.80 | 2019-2022 | |
| Mylan Pharmaceuticals INC. | $68.79 | 2020-2021 | |
| Allergan, INC. | $43.88 | 2019-2020 | |
| Exeltis, USA INC. | $41.90 | 2021 | |
| Evofem Biosciences, INC. | $39.10 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $34.99 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.95 | 2022 | |
| Organon LLC | $33.76 | 2022-2024 | Nexplanon |
| Exact Sciences Corporation | $31.67 | 2023 | Cologuard Collection Kit |
| Lupin INC. | $28.76 | 2020 | |
| Merck Sharp & Dohme LLC | $28.48 | 2019-2024 | Gardasil, Gardasil 9 |
| Olympus America INC. | $21.50 | 2019 | |
| Novo Nordisk INC | $21.40 | 2019 | |
| Agile Therapeutics, INC. | $19.66 | 2023 | Twirla |
| Mission Pharmacal Company | $17.17 | 2019 | |
| Myovant Sciences INC. | $16.41 | 2021 | |
| Sage Therapeutics, LLC | $14.34 | 2022 | |
| Duchesnay USA Incorporated | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roshnara Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.